International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
about
Acute myeloid leukemia in the older adultsA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersEpigenetic therapy in gastrointestinal cancer: the right combinationThe blind men and the AML elephant: can we feel the progress?An update of current treatments for adult acute myeloid leukemiaIDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesNovel therapeutic options in Acute Myeloid Leukemia'Acute myeloid leukemia: a comprehensive review and 2016 update'Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaThe European Hematology Association Roadmap for European Hematology Research: a consensus documentFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupSuccessful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionBridging-to-transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-host Disease.A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsAcute myeloid leukemia: advancing clinical trials and promising therapeutics.Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemiaClinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.Hypomethylating agents after allogeneic blood stem cell transplantation.Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter studyThe Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Isocitrate dehydrogenase mutations in myeloid malignancies.Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.Chemotherapy options for previously untreated acute myeloid leukemia.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Acute myeloid leukemia--major progress over four decades and glimpses into the future.
P2860
Q26740584-5C88AFC3-301F-439F-A217-EBE5CEC06824Q26743743-757382EC-1FAA-4EEB-992A-D6004970C458Q26745709-40D358A6-C48A-4B1D-94D3-6418A59F2BDBQ26749614-A6637B18-EA13-4DFB-B44E-A1A0664E3A7EQ26776396-5BC1D5AD-155B-4EA8-8499-54011A8A733AQ28066926-DD4FBAA4-696D-4E36-B6AA-EB925147CE85Q28069889-52A7E695-B378-46FC-97E5-D7BFD8787042Q28072539-75C6D019-F143-439F-B45B-0D3AC0234116Q28075654-1005FCB3-F747-49F6-A12D-06D02B9D608BQ28084813-F2BAE72B-98A4-4AC7-97EE-57EAB7E9B4F0Q28830861-C79A6333-19B5-46F1-906D-93DF884BCE05Q30244168-95A90586-9B3D-467F-B430-0D8EE67FD550Q31163049-1E4DDBF7-9568-4FA1-999B-174B32DF9409Q32182249-A44F4EB6-DEC7-4AF4-AA34-9C1CD883E125Q33431584-275E7671-A104-447C-B1D7-24C9C8C5FD33Q33434768-BB8F91BE-6191-42FA-8CF4-CF7D7A1D7260Q33437345-13113A57-B380-485B-B8A3-4EEA43E5AD70Q33709905-4EEA96CD-4B7A-45FC-928F-6A6827C37263Q33761979-74C71B30-0139-440B-ADFE-9EDC652DB0C8Q33815617-34E8B114-CAE6-4EED-93B7-7854E74A75E2Q36157664-626762C0-7B33-4C9D-A297-FC7B821A3E62Q36242646-4383237A-A21A-426D-ABC1-949CB676DB6EQ36804633-23AF33C5-503A-43C3-891C-BB45FA1581A6Q37221579-B2BDFF1E-0275-42FF-9497-7EE0EEA61883Q37288474-3B35771F-CFE4-411C-BFDD-836F0D5DCC65Q37327466-9F794B94-0174-4B3A-8EB1-300FE6C0EAD0Q37531039-7A73F0B2-E4C3-4294-B164-EA219D3B955BQ37545335-12CF894D-B9E4-46CB-9B05-8CDD538A073BQ37548245-357175AD-C4E5-44A6-A361-4EEEDC4D4FE3Q37622957-0446D413-2BDD-4A82-AE94-C83B974F85E9Q37624593-FB59F71C-D92F-40F1-8010-9E538D49066EQ37625630-FFBA0F17-EADD-4C81-A996-3B4A8264F66FQ37699158-7CB45C1E-45CE-4F0E-88BB-71F63ED599EAQ37731703-7CADDC91-CC5E-48FA-A8D8-9E7EBF0A4FECQ38407057-CF984D0D-9A25-419C-8CBC-CC984237BB38Q38585930-28113D4F-92D1-4A1A-B40A-1A1512CDCC00Q38601723-9A83DE2A-9948-46C1-ABFE-78CEC37D9DF5Q38614756-305F2385-68FC-46F3-B4A2-DE4C5B9F66B0Q38642017-A57596B8-A600-4E53-8AF0-9AB0050548CEQ38644941-BE39132F-A996-40D1-A356-96CD69037B46
P2860
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
International phase 3 study of ...... iagnosed AML with >30% blasts.
@ast
International phase 3 study of ...... iagnosed AML with >30% blasts.
@en
type
label
International phase 3 study of ...... iagnosed AML with >30% blasts.
@ast
International phase 3 study of ...... iagnosed AML with >30% blasts.
@en
prefLabel
International phase 3 study of ...... iagnosed AML with >30% blasts.
@ast
International phase 3 study of ...... iagnosed AML with >30% blasts.
@en
P2093
P2860
P50
P1433
P1476
International phase 3 study of ...... iagnosed AML with >30% blasts.
@en
P2093
Agnieszka Wierzbowska
Aleksandra Butrym
Andre C Schuh
Anna Candoni
Christian Récher
Dominik Selleslag
Heidi McIntyre
James Cavenagh
John F Seymour
P2860
P304
P356
10.1182/BLOOD-2015-01-621664
P407
P577
2015-05-18T00:00:00Z